COVID-19 mRNA Vaccine Efficacy Wanes Over Time in RCC Cases
Strategies, such as booster doses, appear warranted in this population.
Renal Cell Carcinoma
Trials Investigating Bempegaldesleukin in Combination With Nivolumab Discontinued
The decision to discontinue was based on data from pre-planned analyses of the phase 3 PIVOT-09 study and the phase 2 PIVOT-10 study.
Bevacizumab Biosimilar Alymsys Gets FDA Approval
The approval was based on data demonstrating that the biosimilar product and the reference product were highly similar, and that there were no clinically meaningful differences between the agents.
March 2022: Drug Pipeline Updates
A review of regulatory and drug development status updates.
Allogeneic CAR T-Cell Candidate Fast Tracked for Renal Cell Carcinoma
The investigational product targets CD70, which is highly expressed in renal cell carcinoma with limited normal tissue expression.
Bacterial Supplement May Improve CPI Outcomes in Metastatic Kidney Cancer
In a phase 1 trial, investigators tested whether an oral supplement containing a strain of Clostridium butyricum increases the abundance of certain gut bacteria known to be associated with a better response to immune checkpoint inhibitors.
Immune Checkpoint Inhibitor Combo Therapy Assessed in mRCC Patients With Poor Performance Status
Since patients with poor PS (≥2) were excluded from trials analyzing this new standard of care for mRCC treatment, the study aimed to assess the efficacy and safety of immune checkpoint combination therapy in this group of patients.
Real-World Data Confirm Pazopanib as Safe, Effective in mRCC
Investigators conducted a noninterventional, multicenter study (APOLON) in patients receiving frontline pazopanib therapy.
Study Identifies Treatment Preferences in Advanced Renal Cell Carcinoma
The case-based study aimed to analyze the prescribing behaviors of community oncologists treating patients with aRCC.
ICI-Based Urologic Cancer Therapies Tied to High Adverse Event Rates
Treatment-related adverse events of any grade develop in the majority of patients who receive urologic cancer therapies based on immune checkpoint inhibitors, according to a study.
